1 / 1

Infigratinib(Truseltiq)

Acetylcysteine Injection, FLUIMUCIL, Acetylcysteine InjectionAcetylcysteine Injection, FLUIMUCIL, Acetylcysteine InjectionAcetylcysteine Injection, FLUIMUCIL, Acetylcysteine Injection

Reference price:

Manufacturer:

HELSINN HLTHCARE

Formulation:

CAPSULE

Validity period:

24 months

Reminder: The outer packaging is for reference only, please purchase and use under the guidance of a pharmacist. For read by medical and pharmaceutical professionals only.

Truseltiq(Infigratinib) Instructions:Uses,Dosage, Side Effects

TRUSELTIQ, with the generic name infigratinib, is a small molecule kinase inhibitor. Its primary mechanism of action is the selective targeting and inhibition of fibroblast growth factor receptors (FGFR), particularly FGFR2. It is formulated as hard gelatin capsules for oral use, available in 25 mg and 100 mg strengths. This prescription medication is intended for a specific adult patient population with advanced bile duct cancer that tests positive for certain FGFR2 genetic abnormalities, representing a targeted therapeutic approach.

Generic name

Infigratinib(Truseltiq)

English name

Infigratinib

Alternative Names

Truseltiq

Drug prices

Indications

TRUSELTIQ is indicated for adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma harboring an FGFR2 fusion or rearrangement as detected by an FDA-approved test. This indication received accelerated approval based on overall response rate and duration of response.

Therapeutic Target

Fibroblast growth factor receptor 2 (FGFR2)

Active Ingredients

Infigratinib phosphate

Dosage form

CAPSULE

specifications

(100mg + 25mg) * 21 Capsules/Box

Description

Dosage and Administration

Standard dose: 125 mg once daily for 21 consecutive days, followed by 7 days off, in 28-day cycles.

Take on an empty stomach at least 1 hour before or 2 hours after food.

Swallow capsules whole with water; do not crush, chew, or dissolve.

Dose adjustments are required for mild or moderate renal impairment (100 mg daily) and mild hepatic impairment (100 mg daily) or moderate hepatic impairment (75 mg daily).

Manage adverse reactions with dose interruptions, reductions, or discontinuation as per guidelines.

CATEGORY NAVIGATION